ASPET

JULY 19, 2024

However, limited treatment options are available for those with recurrent disease, and there is a need to identify alternative treatment options for the advanced setting. OKN-007 treatment reduced IDO1, SULF2, and TGF-β protein expression in vivo, and inhibited TGF-β, NF-kB, and AhR- receptor-mediated nuclear signaling in vitro.

Protein Expression 100

Protein Expression Clinical Trials Treatment Regulations 100

Chemical Biology and Drug Design

DECEMBER 6, 2023

Target genes of SP-FC were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), and targets of HS-related diseases were searched from databases such as Disgenet and GeneCards. was employed for protein–protein interaction (PPI) network analysis of common targets; and cytoscape 3.9.0

Molecular Biology 100

Molecular Biology Protein Expression Treatment Regulations 100

The Pharma Data

NOVEMBER 26, 2020

(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

Drug Target Review

APRIL 14, 2025

Traditional biologics often involve recombinant protein expression in mammalian cells or microbes like E. Traditional biologics manufacturing can be complex and expensive, making it difficult to offer affordable therapies for widespread diseases. coli and yeast, but spirulina presents a new set of considerations.

Therapies 52

Therapies Marketing Drug Development Treatment 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. We are excited to be part of the Lyme disease vaccine development program with Valneva. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

DrugBank

JULY 24, 2024

This is a game-changer, especially in the fight against cancer and other complex diseases. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. This can potentially correct the root causes of some diseases at the genetic level.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

The Pharma Data

APRIL 26, 2022

NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Target Review

MAY 4, 2023

These studies are conducted by comparing the genomes of large populations to find variants that occur more often in those with a specific disease or trait. These studies are conducted by comparing the genomes of large populations to find variants that occur more often in those with a specific disease or trait. “A

Disease 52

Disease Small Molecule Protein Expression Research 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Codon

DECEMBER 10, 2023

Predictive models for biology will span all scales, from individual proteins to the culture conditions in which cells grow. Large-scale experiments suggest that <50% of bacterial proteins and <15% of non-bacterial proteins express within E. coli , yeast, and other types of organisms.

Protein Expression 111

Protein Expression Laboratories DNA Engineering 111

Conversations in Drug Development Trends

AUGUST 14, 2024

Heterogeneity in Hematological Cancers Due to their disease heterogeneity, hematological cancers are well-suited for personalized approaches. Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Drug Target Review

OCTOBER 6, 2023

Focusing on SRC-3 within the nucleus activates a series of changes in protein expression that have a profound impact of enhancing the immune system’s ability to engage and attack cancer cells. By working directly at this level in the Treg, CoRegen can precisely manipulate its cellular activity at its source, the TME.

Small Molecule 111

Small Molecule Engineering Protein Expression Therapies 111

Drug Target Review

FEBRUARY 19, 2024

I loved learning how to explain at the molecular level what was happening in nature, in human beings and disease settings. A pivotal moment for me was when I realised that if I understood disease mechanisms on a molecular level, I could be part of an industry that helps develop medicines/therapies for those who need them most.

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Broad Institute

SEPTEMBER 26, 2024

Additionally, astrocyte inflammation has been observed in patients with many neurodegenerative diseases. We hypothesized that these small molecules would similarly decrease the expression of chromatin proteins in hiPSC-derived astrocytes. BSRP is nothing short of transformative.

Small Molecule 52

Small Molecule Protein Expression Disease Science 52

Codon

DECEMBER 10, 2023

Predictive models for biology will span all scales, from individual proteins to the culture conditions in which cells grow. Large-scale experiments suggest that <50% of bacterial proteins and <15% of non-bacterial proteins express within E. coli , yeast, and other types of organisms.

Protein Expression 90

Protein Expression Laboratories DNA Engineering 90

The Pharma Data

MAY 2, 2022

NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other disease areas such as inflammation. View the full release here: [link]. Gilead Sciences, Inc. Source link: [link].

Licensing 52

Licensing Licensing Research Protein Expression 52

PPD

OCTOBER 12, 2023

These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

DECEMBER 8, 2020

Some of the funds will be used for the development of therapeutics for oncology and other serious diseases through its proprietary ImmunoTAC technology platform. The ImmunoTAC platform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. About multiple sclerosis Multiple sclerosis (MS) is a chronic disease that affects nearly 1 million people in the U.S.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

OCREVUS CHIMES study exclusively focused on disease insights and more tailored care for minority populations with MS. We remain committed to advancing the science in MS by investigating potential new medicines such as fenebrutinib, with the ultimate goal of halting progression of this disease,” said Levi Garraway, M.D.,

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

APRIL 8, 2021

OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs). Following U.S.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

Alta Sciences

APRIL 17, 2024

Gene Therapy Gene therapy is currently considered for diseases, often rare, that have no other cures. We have conducted over 130 in-life studies in the last five years (over 95% conducted in NHPs), including IND-enabling studies for rare diseases and CRISPR gene editing therapeutics in NHPs.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

MARCH 30, 2021

Fibroblast activation protein (FAP) is a cell-surface protein expressed at low levels in most normal adult tissues, but over-expressed in common cancers, particularly on cancer-associated fibroblasts that form the tumor stroma, which is essential for growth 1 ,2 ,3 ,4.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

JUNE 7, 2023

1,2 While first-line treatment with immune checkpoint inhibitors with or without chemotherapy has improved outcomes for patients with NSCLC without AGAs, like EGFR or ALK, most patients eventually experience disease progression. 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. months (95% CI: 6.8-11.8)

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

SEPTEMBER 2, 2020

Initiation of Phase III clinical trial programme for fenebrutinib, an investigational medicine designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, which may offer novel approach to suppress disease activity and slow disease progression in MS.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

OCTOBER 28, 2020

Preliminary results from the first five patients treated indicate substantial improvements in all patients in at least two disease domains including communication, behavior, sleep, gross motor function, and fine motor function as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome (CGI-I-AS) at day 128.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

The Anticancer Fund

SEPTEMBER 29, 2021

This drug combination is rationally designed to target multiple escape mechanisms by which refractory disease evades treatment. Data from patients in the clinical trial showed decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumours.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. CHARMs are an elegant solution to the problem of silencing disease genes, and they have the potential to have an important position in the future of genetic medicines.” “The

Disease 142

Disease Therapies Clinical Trials Engineering 142

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

DECEMBER 3, 2020

The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Reducing the Time to Diagnosis and Increasing the Detection of Individuals with SCN1A- related Disease Through a Sponsored Epilepsy Genetic Testing Program.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Target Review

JANUARY 26, 2024

To test whether the mouse-made human ACE2 proteins were functional, the researchers used numerous methods, which included demonstrating that a psuedovirus containing the Covid spike protein could bind to the receptors and infect cells.

Production 114

Production DNA Virus Protein Expression 114

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

SEPTEMBER 28, 2021

Our goal is to still lead the way in developing transformative medicines for neuromuscular diseases. We are grateful for the partnerships that are helping us to develop new therapies for people impacted by these devastating rare diseases.”. About SMA SMA may be a severe, progressive neuromuscular disease which will be fatal.

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

The Pharma Data

APRIL 27, 2022

Up to half of all patients with breast cancer have tumours with a HER2 immunohistochemistry (IHC) score of 1+, or 2+ in combination with a negative in-situ hybridisation (ISH) test, a level of HER2 expression not currently eligible for HER2-targeted therapy. 1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease.

Therapies 52

Therapies Trials Protein Expression Treatment 52

The Pharma Data

AUGUST 9, 2021

The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified and no Grade 4 or 5 treatment-related interstitial lung disease events. Despite initial treatment with trastuzumab and a taxane, patients with HER2-positive metastatic breast cancer will often experience disease progression.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52